AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33931371 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa trigger followed by 1000 IU HCG s.c. on the oocyte retrieval day and 500 IU HCG s.c. 4 days later, no vaginal LPS (Group C)
Number of subjects: 250
Study 33931371 — intervention group
Group type: COMPARATOR
Intervention: 6500 IU HCG trigger and a standard vaginal LPS (Group D)
Number of subjects: 250
Study 32553329 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation drug-eluting stents (DES)
Number of subjects: 19833
Study 32553329 — intervention group
Group type: COMPARATOR
Intervention: First-generation drug-eluting stents (DES)
Number of subjects: 19833
Study 35907864 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity tracker intervention
Number of subjects: 1642
Study 35907864 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity tracker + digital motivational intervention
Number of subjects: 1642
Study 35907864 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1642
Study 33758058 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia (eutectic mixture of lidocaine and prilocaine)
Number of subjects: 136
Study 33758058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 32750393 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month dual anti-platelet therapy (DAPT) followed by 23-month ticagrelor monotherapy
Number of subjects: 3823
Study 32750393 — intervention group
Group type: COMPARATOR
Intervention: 12-month dual anti-platelet therapy (DAPT) followed by 12-month aspirin monotherapy
Number of subjects: 3823
Study 35822607 — intervention group
Group type: COMPARATOR
Intervention: LIA with ropivacaine
Number of subjects: 120
Study 35822607 — intervention group
Group type: COMPARATOR
Intervention: LIA with a new cocktail containing ropivacaine, diprospan, and morphine
Number of subjects: 120
Study 35822607 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 34294062 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced lung function (FEV1 and FVC)
Number of subjects: 132452
Study 34294062 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased liability to COPD
Number of subjects: 132452
Study 34294062 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable Mendelian randomization (MVMR) analysis
Number of subjects: 132452
Study 36247856 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture combined with continuous attendance intervention
Number of subjects: 110
Study 36247856 — intervention group
Group type: COMPARATOR
Intervention: Routine attendance care
Number of subjects: 110
Study 32349698 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Crisis Intervention (MBCI)
Number of subjects: 50
Study 32349698 — intervention group
Group type: COMPARATOR
Intervention: Social Activity Therapy (SAT)
Number of subjects: 50
Study 34099629 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat mass index, % fat mass, body mass index
Number of subjects: 303
Study 34099629 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-free mass index
Number of subjects: 303
Study 34099629 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness
Number of subjects: 303
Study 35977911 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine supplementation (3.2 g/day for 12 weeks)
Number of subjects: 40
Study 35977911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 35977911 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine supplementation
Number of subjects: 40
Study 35071424 — intervention group
Group type: EXPERIMENTAL
Intervention: C-arm navigation method (group A)
Number of subjects: 16
Study 35071424 — intervention group
Group type: COMPARATOR
Intervention: Conventional localization method (group B)
Number of subjects: 16
Study 35219171 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (150 min/week of moderate-intense aerobic activity)
Number of subjects: 117
Study 35219171 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard medical care only)
Number of subjects: 117
Study 35219171 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 117
Study 35219171 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 117
Study 34816666 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangeretin (200 mg/day)
Number of subjects: 24
Study 32985283 — intervention group
Group type: EXPERIMENTAL
Intervention: Cat-keeping at home
Number of subjects: 11611
Study 32985283 — intervention group
Group type: EXPERIMENTAL
Intervention: Poultry-keeping at home
Number of subjects: 11611
Study 32985283 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeping with pets
Number of subjects: 11611
Study 32066839 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up cohort study
Number of subjects: 5072
Study 32066839 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of diabetes
Number of subjects: 5072
Study 32066839 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of known diabetes
Number of subjects: 5072
Study 35456349 — intervention group
Group type: EXPERIMENTAL
Intervention: Common hepatic artery reconstruction
Number of subjects: 25
Study 35456349 — intervention group
Group type: COMPARATOR
Intervention: Non-reconstructed group
Number of subjects: 25
Study 33213494 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHu‐EPO) 10000 IU subcutaneous injection after operation and once daily for the next week
Number of subjects: 152
Study 33213494 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHu‐EPO)
Number of subjects: 152
Study 33213494 — intervention group
Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 152
Study 33808652 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K (400 µg MK‐7/day) and vitamin D3 (80 µg/day)
Number of subjects: 52
Study 33808652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 35386097 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated mechanical peripheral stimulation (AMPS)
Number of subjects: 28
Study 35386097 — intervention group
Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 28
Study 33754184 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral resorbable diet (ED) with peristalsis-inhibiting medication
Number of subjects: 66
Study 33754184 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (SD)
Number of subjects: 66
Study 33142437 — intervention group
Group type: EXPERIMENTAL
Intervention: Water pool (WP)
Number of subjects: 120
Study 33142437 — intervention group
Group type: COMPARATOR
Intervention: Lack of access to water pool (LWP)
Number of subjects: 120
Study 33100212 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cream of Malva sylvestris extract, applied twice daily for 4 weeks.
Number of subjects: 51
Study 33100212 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream, applied twice daily for 4 weeks.
Number of subjects: 51
Study 32212024 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mmHg, 2 s compressive stimulus below heart level
Number of subjects: 12
Study 32212024 — intervention group
Group type: COMPARATOR
Intervention: 200 mmHg, 2 s compressive stimulus above heart level
Number of subjects: 12
Study 32212024 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing pressure of compressive stimulus
Number of subjects: 12
Study 32212024 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing duration of compressive stimulus
Number of subjects: 12
Study 35115097 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 4614
Study 35115097 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 4614
Study 34591022 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention delivered by peer educator
Number of subjects: 138
Study 34591022 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention delivered by clinician
Number of subjects: 138
Study 34591022 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (peer and clinician)
Number of subjects: 138
Study 34591022 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider narrator
Number of subjects: 138
Study 35346319 — intervention group
Group type: EXPERIMENTAL
Intervention: Awake prone positioning (APP)
Number of subjects: 430
Study 35346319 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 430
Study 34002215 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise layered provisional strategy
Number of subjects: 467
Study 34002215 — intervention group
Group type: COMPARATOR
Intervention: Systematic dual stent approach
Number of subjects: 467
Study 32783942 — intervention group
Group type: EXPERIMENTAL
Intervention: CRISPR-based multi-gene knockout screening system
Number of subjects: 0
Study 33731145 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutri-Score
Number of subjects: 3382
Study 33731145 — intervention group
Group type: COMPARATOR
Intervention: Reference Intakes
Number of subjects: 3382
Study 33731145 — intervention group
Group type: COMPARATOR
Intervention: No label
Number of subjects: 3382
Study 32907575 — intervention group
Group type: EXPERIMENTAL
Intervention: Navafenterol 900 μg
Number of subjects: 24
Study 32907575 — intervention group
Group type: EXPERIMENTAL
Intervention: Navafenterol 300 μg
Number of subjects: 24
Study 32907575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 32907575 — intervention group
Group type: EXPERIMENTAL
Intervention: Navafenterol (all doses)
Number of subjects: 24
Study 32907575 — intervention group
Group type: EXPERIMENTAL
Intervention: Navafenterol
Number of subjects: 24
Study 33188138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ceftriaxone followed by 5 days of azithromycin and metronidazole (IA)
Number of subjects: 313
Study 33188138 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SoC) of 14 days of ofloxacin and metronidazole
Number of subjects: 313
Study 34047268 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal depressive symptoms
Number of subjects: 405
Study 34047268 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vocabulary
Number of subjects: 405
Study 34047268 — intervention group
Group type: EXPERIMENTAL
Intervention: Indulgent feeding
Number of subjects: 405
Study 34047268 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast‐feeding at 1 year
Number of subjects: 405
Study 34047268 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal education, BMI, occupation
Number of subjects: 405
Study 32592694 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned cesarean delivery
Number of subjects: 1393
Study 32592694 — intervention group
Group type: COMPARATOR
Intervention: Planned vaginal delivery
Number of subjects: 1393
Study 34932202 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 54
Study 34932202 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 54
Study 33957190 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Health Education Program combined with routine dental treatment (OHEPDT)
Number of subjects: 295
Study 33957190 — intervention group
Group type: COMPARATOR
Intervention: Dental treatment alone (DT)
Number of subjects: 295
Study 32122717 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal immobilization at 0° angle (Group 1)
Number of subjects: 80
Study 32122717 — intervention group
Group type: COMPARATOR
Intervention: Spinal immobilization at 20° angle (Group 2)
Number of subjects: 80
Study 32122717 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of ΔETCO2 levels between Groups 1 and 2
Number of subjects: 80
Study 35181391 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 0
Study 33320198 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum concentrations of metabolites of phosphate
Number of subjects: 186
Study 33320198 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum concentrations of N-acetyl-d-glucosamine
Number of subjects: 186
Study 33320198 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum concentrations of branched chained amino acids (BCAAs)
Number of subjects: 186
Study 33320198 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum concentrations of proline
Number of subjects: 186
Study 33320198 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum concentrations of urea
Number of subjects: 186
Study 33320198 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum concentrations of pyroglutamic acid
Number of subjects: 186
Study 33320198 — intervention group
Group type: COMPARATOR
Intervention: 15 metabolites in women with fast decline (tertile 3)
Number of subjects: 186
Study 33931498 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 5), Paclitaxel (175 mg/m2), and Bevacizumab (15 mg/kg) for six 3-weekly cycles followed by Bevacizumab single agent (15 mg/kg) until progression or unacceptable toxicity
Number of subjects: 398
Study 34154431 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month physical activity group program (two walks per week and a monthly visit to a sociocultural facility)
Number of subjects: 150
Study 34154431 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study 35246243 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacerein 50 mg once-daily (n=18)
Number of subjects: 25
Study 35246243 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=17)
Number of subjects: 25
Study 32946077 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg, Cialis®)
Number of subjects: 12
Study 32946077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 32946077 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Tadalafil and Placebo)
Number of subjects: 12
Study 34129153 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabrafenib–trametinib
Number of subjects: 1
Study 34129153 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 1
Study 34129153 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 1
Study 33491369 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic calcium phosphate (β‐TCP/HA)
Number of subjects: 20
Study 33491369 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyapatite (HA)
Number of subjects: 20
Study 35144179 — intervention group
Group type: COMPARATOR
Intervention: Parallel group (SA 0°−3°)
Number of subjects: 160
Study 35144179 — intervention group
Group type: EXPERIMENTAL
Intervention: Lordotic group (SA > 3°)
Number of subjects: 160
Study 34812472 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination taping
Number of subjects: 36
Study 34812472 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle foot orthosis
Number of subjects: 36
Study 34812472 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional physical therapy)
Number of subjects: 36
Study 616642085 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron intervention (point-of-use fortification with micronutrient powders containing vitamins and minerals with iron)
Number of subjects: 1943
Study 616642085 — intervention group
Group type: COMPARATOR
Intervention: No-iron group (control)
Number of subjects: 1943
Study 616642085 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (combined analysis)
Number of subjects: 1943
Study 35720389 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal anti-SARS-CoV-2 RBD IgY
Number of subjects: 48
Study 35720389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 33541100 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrolled group
Number of subjects: 2190
Study 33541100 — intervention group
Group type: COMPARATOR
Intervention: Nonenrolled group
Number of subjects: 2190
Study 33541100 — intervention group
Group type: COMPARATOR
Intervention: Eligible group
Number of subjects: 2190
Study 33541100 — intervention group
Group type: COMPARATOR
Intervention: Ineligible group
Number of subjects: 2190
Study 32681118 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Exercise (MICE) at 24.6% POpeak
Number of subjects: 10
Study 32681118 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE) at 70% POpeak
Number of subjects: 10
Study 32681118 — intervention group
Group type: COMPARATOR
Intervention: Comparison of MICE and HIIE
Number of subjects: 10
Study 34259850 — intervention group
Group type: EXPERIMENTAL
Intervention: Chuna manual therapy
Number of subjects: 108
Study 34259850 — intervention group
Group type: COMPARATOR
Intervention: Usual care (electrotherapy and oral medication)
Number of subjects: 108
Study 35443106 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7442 (300 mg, two consecutive intramuscular injections of tixagevimab and cilgavimab)
Number of subjects: 5197
Study 35443106 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 5197
Study 35443106 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD7442 (300 mg)
Number of subjects: 5197
Study 34219259 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenogeneic collagen matrix (XCM)
Number of subjects: 26
Study 34219259 — intervention group
Group type: COMPARATOR
Intervention: Free gingival grafts (FGG)
Number of subjects: 26
Study 34219259 — intervention group
Group type: EXPERIMENTAL
Intervention: XCM
Number of subjects: 26
Study 34219259 — intervention group
Group type: COMPARATOR
Intervention: FGG
Number of subjects: 26
Study 34219259 — intervention group
Group type: EXPERIMENTAL
Intervention: Both XCM and FGG
Number of subjects: 26
Study 35264684 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum during preoperative fasting
Number of subjects: 94
Study 35264684 — intervention group
Group type: COMPARATOR
Intervention: Conventional fasting
Number of subjects: 94
Study 33213070 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (Vit C)
Number of subjects: 97
Study 33213070 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (Vit E)
Number of subjects: 97
Study 33213070 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 97
Study 33213070 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (MT)
Number of subjects: 97
Study 33213070 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 97
Study 35909001 — intervention group
Group type: COMPARATOR
Intervention: Breast milk plasmalogens (BM pPEs)
Number of subjects: 39
Study 35909001 — intervention group
Group type: COMPARATOR
Intervention: Maternal body mass index
Number of subjects: 39
Study 35909001 — intervention group
Group type: COMPARATOR
Intervention: Maternal fatty acid intake, gestational age, and days postpartum
Number of subjects: 39
Study 34900800 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity laser irradiation (LILI)
Number of subjects: 75
Study 34900800 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT)
Number of subjects: 75
Study 34900800 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional wound care)
Number of subjects: 75
Study 35059703 — intervention group
Group type: EXPERIMENTAL
Intervention: DLPFC stimulation
Number of subjects: 34
Study 35059703 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 34
Study 34694070 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined metabolic activators (CMA)
Number of subjects: 0
Study 34694070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36158127 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized placement and PICC placement care
Number of subjects: 80
Study 36158127 — intervention group
Group type: COMPARATOR
Intervention: Routine PICC placement and catheter maintenance
Number of subjects: 80
Study 32372159 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidermal vacuum wound dressing (VAC)
Number of subjects: 31
Study 32372159 — intervention group
Group type: COMPARATOR
Intervention: Conventional wound care (CONV)
Number of subjects: 31
Study 35550707 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% Pueraria mirifica vaginal gel
Number of subjects: 72
Study 35550707 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 72
Study 34454883 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning prediction model for CRT response
Number of subjects: 741
Study 34454883 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive lasso model
Number of subjects: 741
Study 34454883 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants in the 5th quintile of the prediction model
Number of subjects: 741
Study 34454883 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model
Number of subjects: 741
Study 33413491 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based menu planning intervention
Number of subjects: 54
Study 33413491 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 54
Study 32081463 — intervention group
Group type: EXPERIMENTAL
Intervention: mirvetuximab soravtansine (6 mg/kg, adjusted ideal body weight) and bevacizumab (15 mg/kg)
Number of subjects: 66
Study 32081463 — intervention group
Group type: EXPERIMENTAL
Intervention: mirvetuximab soravtansine and bevacizumab
Number of subjects: 66
Study 36670359 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin, esomeprazole, and amoxicillin
Number of subjects: 270
Study 36670359 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin, esomeprazole, and amoxicillin
Number of subjects: 270
Study 34407543 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib 45 mg once daily
Number of subjects: 283
Study 34407543 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib 30 mg once daily
Number of subjects: 283
Study 34407543 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib 15 mg once daily
Number of subjects: 283
Study 34407543 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib 45 mg and 30 mg (reduced to 15 mg upon response)
Number of subjects: 283
Study 32928279 — intervention group
Group type: EXPERIMENTAL
Intervention: GV‐971 600 mg
Number of subjects: 242
Study 32928279 — intervention group
Group type: EXPERIMENTAL
Intervention: GV‐971 900 mg
Number of subjects: 242
Study 32928279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242